ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.2594del (p.Lys865fs)

dbSNP: rs80357756
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000077523 SCV000299791 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Labcorp Genetics (formerly Invitae), Labcorp RCV000047891 SCV000075904 pathogenic Hereditary breast ovarian cancer syndrome 2015-09-07 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Truncating variants in BRCA1 are known to be pathogenic. This particular truncation has been reported in identical twins, both with ovarian cancer (PMID: 9406579). This variant is also known as 2711delA in the literature. This sequence change deletes 1 nucleotide from exon 10 of the BRCA1 mRNA (c.2594delA), causing a frameshift at codon 865. This creates a premature translational stop signal (p.Lys865Serfs*28) and is expected to result in an absent or disrupted protein product.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000505972 SCV000602722 pathogenic not specified 2017-01-25 criteria provided, single submitter clinical testing
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. RCV000578073 SCV000679702 pathogenic Hereditary cancer-predisposing syndrome 2017-07-12 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002477167 SCV002793448 pathogenic Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S 2021-12-05 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000578073 SCV004360266 pathogenic Hereditary cancer-predisposing syndrome 2023-06-26 criteria provided, single submitter clinical testing This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in two siblings both affected with ovarian cancer (PMID: 9406579). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Ambry Genetics RCV000578073 SCV005025766 pathogenic Hereditary cancer-predisposing syndrome 2023-12-14 criteria provided, single submitter clinical testing The c.2594delA pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 2594, causing a translational frameshift with a predicted alternate stop codon (p.K865Sfs*28). This alteration has been identified in families with history of breast and ovarian cancers (Miesfeldt S et al. Cancer Genet Cytogenet, 1998 Jan;100:43-8). (Flaum N et al. Genet Med, 2022 Dec;24:2578-2586). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Sharing Clinical Reports Project (SCRP) RCV000077523 SCV000109324 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2007-09-24 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077523 SCV000144485 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 1999-04-06 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto RCV000047891 SCV000587234 pathogenic Hereditary breast ovarian cancer syndrome 2014-01-31 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.